Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

About this update from Ironwood Pharmaceuticals, Inc.

BOSTON --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7 th at 12:00 p.m. ET at the New York Hilton Midtown . A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com . A replay of the webcast will be available on Ironwood’s website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts , with a site in Basel, Switzerland . We routinely post information that may be important to investors on our website at www.ironwoodpharma.com . In addition, follow us on X and on LinkedIn . View source version on businesswire.com : https://www.businesswire.com/news/home/20250430201599/en/ Company contact: Greg Martini [email protected] Investors: Precision AQ (formerly Stern Investor Relations) Stephanie Ascher [email protected] Source: Ironwood Pharmaceuticals, Inc.

View stock analysis, news, and events for Ironwood Pharmaceuticals, Inc.